Hafnium Oxide
drug drugOn this page
Also known as Nbtxr3NSC-158931
Summary
Hafnium Oxide (CHEMBL4298051) is a phase-3 clinical-stage unknown; indicated across 3 conditions including head and neck squamous cell carcinoma and soft tissue sarcoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 3 conditions
- Clinical trials: 4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4298051 |
| Name | Hafnium Oxide |
| Type | Unknown |
| Max phase | 3 |
Also known as: Hafnium oxide, Nbtxr3, NBTXR3, NSC-158931, HAFNIUM OXIDE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| head and neck squamous cell carcinoma | 3 | MONDO:0010150 | EFO:0000181 |
| soft tissue sarcoma | 2 | MONDO:0018078 | EFO:1001968 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02379845 | PHASE2/PHASE3 | COMPLETED | NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall |
| NCT07224152 | PHASE1/PHASE2 | RECRUITING | NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer |
| NCT03589339 | PHASE1 | ACTIVE_NOT_RECRUITING | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy |
| NCT01433068 | PHASE1 | COMPLETED | NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma of the Extremity |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- In clinical trials for: head and neck squamous cell carcinoma, soft tissue sarcoma